Genetic Analysis Balance Sheet Health
Financial Health criteria checks 4/6
Genetic Analysis has a total shareholder equity of NOK32.0M and total debt of NOK700.0K, which brings its debt-to-equity ratio to 2.2%. Its total assets and total liabilities are NOK53.5M and NOK21.5M respectively.
Key information
2.2%
Debt to equity ratio
kr700.00k
Debt
Interest coverage ratio | n/a |
Cash | kr16.29m |
Equity | kr32.00m |
Total liabilities | kr21.49m |
Total assets | kr53.49m |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: GEAN's short term assets (NOK29.1M) exceed its short term liabilities (NOK16.0M).
Long Term Liabilities: GEAN's short term assets (NOK29.1M) exceed its long term liabilities (NOK5.4M).
Debt to Equity History and Analysis
Debt Level: GEAN has more cash than its total debt.
Reducing Debt: GEAN's debt to equity ratio has reduced from 3.9% to 2.2% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: GEAN has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: GEAN has less than a year of cash runway if free cash flow continues to reduce at historical rates of 2.9% each year